Table 3.
Summary of Platform Results by Minimum Inhibitory Concentration Susceptibility Status
| Platform | Ceftolozane/Tazobactam | Ceftazidime/Avibactam | |||||
|---|---|---|---|---|---|---|---|
| S (N = 144) | R (N = 53) | Total (N = 197) | S (N = 152) | R (N = 45) | Total (N = 197) | ||
| VERIGENE gram-negative blood culture test | Negative | 144 (100%) | 18 (34%) | 162 (82%) | 152 (100%) | 30 (67%) | 182 (92%) |
| Positive | 0 (0%) | 35 (66%) | 35 (18%) | 0 (0%) | 15 (33%) | 15 (8%) | |
| Acuitas Resistome test | Negative | 144 (100%) | 18 (34%) | 162 (82%) | 152 (100%) | 30 (67%) | 182 (92%) |
| Positive | 0 (0%) | 35 (66%) | 35 (18%) | 0 (0%) | 15 (33%) | 15 (8%) | |
All carbapenemase genes were queried for the ceftolozane/tazobactam predictive analysis; only the blaNDM, -VIM, -IMP genes were included in the ceftazidime/avibactam predictive analysis. For the purposes of this study, an intermediate phenotype was also considered as R.
Abbreviations: R, resistant; S, susceptible.